References
- Lisnevskaia L, Murphy G, Isenberg DA. Systemic lupus erythematosus. Lancet. 2014;384:1878–1882.
- Ramos L, Isenberg DA. Rituximab: the lupus journey. Curr Treat Opt Rheumatol. 2015;1:30–41.
- Merrill JT, Neuwelt CM, Wallace DM. Efficacy and safety of rituximab treatment in moderately-to-severely active systemic lupus erythematosus: the randomized double-blind phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:232–233.
- Rovis BH, Furie R, Latinis K for the LUNAR investigation group, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–1226.
- Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health quality of life outcomes and corticosteroid use in the randomized alleviate trials and extension study SL0006. Rheumatology. 2014;53:512–521.
- Navarra SV, Guzman RM, Gallacho AF, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized placebo-controlled phase III trial. Lancet. 2011;377:721–733.
- Furie R, Petri M, Zameni O, et al A phase III randomized, placebo-controlled study of belimumab, a monoclonal study that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930.
- Isenberg DA, Urowitz M, Merrill J, et al. Efficacy and Safety of subcutaneous tabalumab in patients with systemic lupus erythematosus (SLE): results from 2 phase 3, 52-week, multicenter, randomized, double-blind, placebo-controlled trials. Ann Rheum Dis. Forthcoming 2014.
- Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalimumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52 week, phase II multicentre randomized, double-blind placebo-controlled trial. Ann Rheum Dis. 2015 Sep 3. [Epub ahead of print].
- Isenberg DA, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate to severe systemic lupus erythematosus. Ann Rheum Dis. 2015;74:2006–2015.
- Khamashta M, Merrill J, Werth V, et al. Safety and efficacy of sifalimumab an anti-IFNα monoclonal antibody in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheum. 2014; ACR Abstract number 25.
- Kalunian K, Merrill J, Macivca R, et al. Efficacy and safety of ronalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppression use: results of a randomized, double-blind, placebo controlled phase II study. Arthritis Rheum. 2014;64(Suppl 10):2622.
- Isenberg DA, Gordon C, Merrill J, et al. New in therapies in systemic lupus erythematosus – trials, troubles and tribulations…working towards a solution. Lupus. 2008;17:967–970.
- Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol. 2015;11:616–620.
- Croca S, Rodrigues T, Isenberg DA. Assessment of lupus nephritis cohort over a 30-year period. Rheumatology. 2011;50:1424–1430.
- Carter L, Isenberg DA, Ehrenstein MR. Elevated BAFF levels are associated with rising anti-double stranded DNA antibody levels and disease flare following B-cell depletion therapy. Arthritis Rheum. 2015;65:2672–2679.
- Van Vollenhoven RF, Petri MA, Cervera R. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;8:1343–1349.
- Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steorids. Ann Rheum Dis. 2013;72:1280–1286.